Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
2
Upcoming Catalysts
1
Historical Events
2
Regulatory Approvals
0 competitors in Advanced Hepatocellular Carcinoma
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Tremelimumab AstraZeneca
Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.
View on EMAImjudo
Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.
View on EMAIrritable Bowel Syndrome With Constipation (IBS-C)
Muscle Invasive Bladder Cancer
Asthma, Exercise-Induced
Affective Psychosis, Bipolar
Carcinoma, Non-Small-Cell Lung